心脏干细胞输注缺血性心肌病患者I期临床试验
2011-11-15 21:53:00 来源:
Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)
This study is ongoing, but not recruiting participants.
First Received on May 15, 2007. Last Updated on August 30, 2011 History of Changes
Sponsor: University of Louisville
Collaborators: Brigham and Women's Hospital
Jewish Hospital and St. Mary's Healthcare
Information provided by (Responsible Party): Roberto Bolli, University of Louisville
ClinicalTrials.gov Identifier: NCT00474461
Purpose
The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack.
The central hypothesis is that CSCs infused into nonviable myocardial segments will regenerate infarcted myocardium by differentiating into cardiomyocytes and other cell types. According to our hypothesis, CSC infusion regenerates myocardium with consequent improvement in contractile function of the heart and general clinical status.
Condition
Intervention
Phase
Coronary Artery Disease
Congestive Heart Failure Procedure: Intracoronary Injection (cardiac stem cell therapy) Phase I
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients With Ischemic Cardiomyopathy.
Resource links provided by NLM:
MedlinePlus related topics: Cardiomyopathy Coronary Artery Disease Heart Attack Heart Failure
U.S. FDA Resources
Further study details as provided by University of Louisville:
Primary Outcome Measures:
• Monitoring adverse outcomes, death, sustained/symptomatic ventricular tachycardia, infection, bleeding, MI, stroke, peripheral embolism in the hospital after drug administration, in the first month after injection, and serially afterwards. [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 40
Study Start Date: February 2009
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Intervention Details:
Procedure: Intracoronary Injection (cardiac stem cell therapy)
Intracoronary injection of cardiac stem cells
Show Detailed Description
Eligibility
Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
• LVEF < 40% (by any imaging modality: echocardiography/SPECT/LV angiography)
• A history of Q-wave MI with a residual akinetic and nonviable scar (as evidenced by low-dose dobutamine stress echocardiogram and/or or thallium redistribution nuclear study for viability and/or an electrocardiogram)
• Patients scheduled for surgical revascularization within few days (< 2 weeks) of the initial screening
Exclusion Criteria:
• Age >75 by time of infusion
• Cardiogenic shock
• Severe co-morbidities (e.g., renal failure, liver failure)
• Mini-CABG procedures
• Pregnant/nursing women or women of child-bearing potential
• Inability to provide informed consent
• Diabetic Hgb A1c > 8.5%
• Patients with a history of hepatitis B, hepatitis C, and HIV
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00474461
Locations
United States, Kentucky
Jewish Hospital
Louisville, Kentucky, United States, 40202
Sponsors and Collaborators
University of Louisville
Brigham and Women's Hospital
Jewish Hospital and St. Mary's Healthcare
Investigators
Principal Investigator: Roberto Bolli, MD University of Louisville
More Information
No publications provided
Responsible Party: Roberto Bolli, University of Louisville
ClinicalTrials.gov Identifier: NCT00474461 History of Changes
Other Study ID Numbers: IOIC070833
Study First Received: May 15, 2007
Last Updated: August 30, 2011
Health Authority: United States: Food and Drug Administration
Keywords provided by University of Louisville:
coronary artery disease
Heart Attack
Heart failure
Cardiac Stem Cells
Coronary Artery Bypass
Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Failure
Cardiomyopathies Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
ClinicalTrials.gov processed this record on November 15, 2011
This study is ongoing, but not recruiting participants.
First Received on May 15, 2007. Last Updated on August 30, 2011 History of Changes
Sponsor: University of Louisville
Collaborators: Brigham and Women's Hospital
Jewish Hospital and St. Mary's Healthcare
Information provided by (Responsible Party): Roberto Bolli, University of Louisville
ClinicalTrials.gov Identifier: NCT00474461
Purpose
The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack.
The central hypothesis is that CSCs infused into nonviable myocardial segments will regenerate infarcted myocardium by differentiating into cardiomyocytes and other cell types. According to our hypothesis, CSC infusion regenerates myocardium with consequent improvement in contractile function of the heart and general clinical status.
Condition
Intervention
Phase
Coronary Artery Disease
Congestive Heart Failure Procedure: Intracoronary Injection (cardiac stem cell therapy) Phase I
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients With Ischemic Cardiomyopathy.
Resource links provided by NLM:
MedlinePlus related topics: Cardiomyopathy Coronary Artery Disease Heart Attack Heart Failure
U.S. FDA Resources
Further study details as provided by University of Louisville:
Primary Outcome Measures:
• Monitoring adverse outcomes, death, sustained/symptomatic ventricular tachycardia, infection, bleeding, MI, stroke, peripheral embolism in the hospital after drug administration, in the first month after injection, and serially afterwards. [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 40
Study Start Date: February 2009
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Intervention Details:
Procedure: Intracoronary Injection (cardiac stem cell therapy)
Intracoronary injection of cardiac stem cells
Show Detailed Description
Eligibility
Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
• LVEF < 40% (by any imaging modality: echocardiography/SPECT/LV angiography)
• A history of Q-wave MI with a residual akinetic and nonviable scar (as evidenced by low-dose dobutamine stress echocardiogram and/or or thallium redistribution nuclear study for viability and/or an electrocardiogram)
• Patients scheduled for surgical revascularization within few days (< 2 weeks) of the initial screening
Exclusion Criteria:
• Age >75 by time of infusion
• Cardiogenic shock
• Severe co-morbidities (e.g., renal failure, liver failure)
• Mini-CABG procedures
• Pregnant/nursing women or women of child-bearing potential
• Inability to provide informed consent
• Diabetic Hgb A1c > 8.5%
• Patients with a history of hepatitis B, hepatitis C, and HIV
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00474461
Locations
United States, Kentucky
Jewish Hospital
Louisville, Kentucky, United States, 40202
Sponsors and Collaborators
University of Louisville
Brigham and Women's Hospital
Jewish Hospital and St. Mary's Healthcare
Investigators
Principal Investigator: Roberto Bolli, MD University of Louisville
More Information
No publications provided
Responsible Party: Roberto Bolli, University of Louisville
ClinicalTrials.gov Identifier: NCT00474461 History of Changes
Other Study ID Numbers: IOIC070833
Study First Received: May 15, 2007
Last Updated: August 30, 2011
Health Authority: United States: Food and Drug Administration
Keywords provided by University of Louisville:
coronary artery disease
Heart Attack
Heart failure
Cardiac Stem Cells
Coronary Artery Bypass
Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Failure
Cardiomyopathies Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
ClinicalTrials.gov processed this record on November 15, 2011
上一篇:全球首例人类胚胎干细胞临床试验因费用过高被终止
下一篇:日本京都大学医院将成立多能干细胞门诊
延伸阅读:
- ·Prochymal显着降低心脏病发作患者肥大 心律失常和心力衰竭的进展(2013-05-24)
- ·迄今为止最大规模的心脏干细胞临床研究收锚启航(2013-05-30)
- ·FDA细胞治疗心脏病指导意见(2013-07-15)
- ·修复损伤心脏组织的纳米纤维支架及方法[美国专利](2013-07-29)
- ·心脏祖细胞培养及应用方法[美国专利](2013-11-22)
分享到:
收藏
频道总排行
频道今日排行
- 3,5762014Q2——生物技术行业走上正轨
- 3,574iPS细胞缓步走向临床
- 3,573全球首例胚胎干细胞疗法试验夭折 成人干细胞研究进展良好
- 3,572哈佛干细胞专家:干细胞技术魅力在于让新药更低价
- 3,572争议干细胞疗法 意大利批准使用
- 3,572诺华敲定与干细胞公司Gamida的交易
- 3,572高丝利用iPS细胞开发化妆品?
- 3,572FDA 美国杜克大学医学院脐带血造血干细胞静脉注射悬浮液...
- 3,572十一位科学家获生命科学巨奖
- 3,571美国先进细胞科技公司开展干细胞治疗眼疾临床试验 效果显著